OncoMatch/Clinical Trials/NCT05765877
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Is NCT05765877 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies WX-0593 Tablets for non-small cell lung cancer(nsclc).
Treatment: WX-0593 Tablets — This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK fusion
ALK-positive
Required: ROS1 fusion
ROS1-positive
Disease stage
Required: Stage IB, IIA, IIB, IIIA (8th American Joint Committee on Cancer TNM edition)
ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on Cancer TNM edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug
Cannot have received: ALK inhibitor
Prior treatment with ALK TKI
Cannot have received: ROS1 inhibitor
Prior treatment with ... ROS1 TKI
Cannot have received: radiation therapy
Prior treatment with local radiotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05765877 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK fusion is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage IB or IIA or IIB or IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify